The Francis Crick Institute
91868.2-20170412122937-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf (1.67 MB)

M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza

Download (1.67 MB)
journal contribution
posted on 2020-06-26, 09:47 authored by Suzanne L Cole, Jake Dunning, Wai Ling Kok, Kambez Hajipouran Benam, Adel Benlahrech, Emmanouela Repapi, Fernando O Martinez, Lydia Drumright, Timothy J Powell, Michael Bennett, Ruth Elderfield, Catherine Thomas, MOSAIC investigators, Tao Dong, John McCauley, Foo Y Liew, Stephen Taylor, Maria Zambon, Wendy Barclay, Vincenzo Cerundolo, Peter J Openshaw, Andrew J McMichael, Ling-Pei Ho
In each influenza season, a distinct group of young, otherwise healthy individuals with no risk factors succumbs to life-threatening infection. To better understand the cause for this, we analyzed a broad range of immune responses in bloodfrom a unique cohort of patients, comprising previously healthy individuals hospitalized with and without respiratory failureduring one influenza season, and infected with one specific influenza A strain. This analysis was compared with similarlyhospitalized influenza patients with known risk factors (total of n = 60 patients recruited). We found a sustained increase ina specific subset of proinflammatory monocytes, with high TNF-α expression and an M1-like phenotype (independent ofviral titers), in these previously healthy patients with severe disease. The relationship between M1-like monocytes andimmunopathology was strengthened using murine models of influenza, in which severe infection generated using differentmodels (including the high-pathogenicity H5N1 strain) was also accompanied by high levels of circulating M1-likemonocytes. Additionally, a raised M1/M2 macrophage ratio in the lungs was observed. These studies identify a specificsubtype of monocytes as a modifiable immunological determinant of disease severity in this subgroup of severely ill,previously healthy patients, offering potential novel therapeutic avenues